Michael Murphy
Research
Publications
2023
IL17A mRNA Staining Distinguishes Palmoplantar Psoriasis from Hyperkeratotic Palmoplantar Eczema in Diagnostic Skin Biopsies
Chen J, Murphy M, Singh K, Wang A, Chow R, Kim R, Cohen J, Ko C, Damsky W. IL17A mRNA Staining Distinguishes Palmoplantar Psoriasis from Hyperkeratotic Palmoplantar Eczema in Diagnostic Skin Biopsies. JID Innovations 2023, 3: 100189. PMID: 37205304, PMCID: PMC10186614, DOI: 10.1016/j.xjidi.2023.100189.Peer-Reviewed Original ResearchMycosis fungoides palmaris et plantarisPalmoplantar psoriasisNonacral sitesPalmoplantar eczemaMRNA expressionAcral skinIL-13 expressionPalmaris et plantarisDiagnostic skin biopsyDermatopathology databaseIL-17AHistopathologic featuresClinical managementBiopsy specimensSkin biopsiesCytokine biomarkersUseful biomarkerEczemaPsoriasisDiagnostic clarityMRNA stainingDermatosesBiomarkersSitu hybridizationSkin
2022
Association of sarcoidosis with psoriasis: a cross-sectional study in the All of Us research program
Murphy M, Leasure A, Damsky W, Cohen J. Association of sarcoidosis with psoriasis: a cross-sectional study in the All of Us research program. Archives Of Dermatological Research 2022, 315: 1439-1441. PMID: 36436011, DOI: 10.1007/s00403-022-02488-z.Peer-Reviewed Original ResearchConceptsCross-sectional studyMatched cross-sectional studyAssociation of sarcoidosisCoexistence of sarcoidosisCommon genetic susceptibilitySimilar immunopathogenesisCardiopulmonary symptomsPsoriasis patientsInflammatory skinMultivariable analysisSystemic diseasePsoriasis casesProgram databaseImmune responseSarcoidosisPsoriasisUs Research ProgramPotential associationGenetic susceptibilityDiseaseImmunopathogenesisAssociationSame individualFurther researchTh1Utilization, cost, and prescription patterns of dupilumab among Medicare beneficiaries in the United States from 2017 to 2019
Murphy MJ, Cheraghlou S, Damsky W, Cohen JM. Utilization, cost, and prescription patterns of dupilumab among Medicare beneficiaries in the United States from 2017 to 2019. Journal Of Dermatological Treatment 2022, 33: 3214-3215. PMID: 36137225, DOI: 10.1080/09546634.2022.2127304.Peer-Reviewed Original ResearchInhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis
Damsky W, Wang A, Kim DJ, Young BD, Singh K, Murphy MJ, Daccache J, Clark A, Ayasun R, Ryu C, McGeary MK, Odell ID, Fazzone-Chettiar R, Pucar D, Homer R, Gulati M, Miller EJ, Bosenberg M, Flavell RA, King B. Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nature Communications 2022, 13: 3140. PMID: 35668129, PMCID: PMC9170782, DOI: 10.1038/s41467-022-30615-x.Peer-Reviewed Original ResearchConceptsType 1 immunityInternal organ involvementOrgan involvementT cell-derived IFNIdiopathic inflammatory disorderOpen-label trialMonths of treatmentType 1 cytokinesJanus kinase inhibitorImmunologic changesLongstanding sarcoidosisSarcoidosis activitySarcoidosis symptomsClinical improvementCutaneous sarcoidosisSecondary outcomesComplete responsePrimary outcomeTofacitinib treatmentActivity scoreCytokine mediatorsIL-12IL-15IL-6Inflammatory disorders
2021
Treatment of Persistent Erythema Multiforme With Janus Kinase Inhibition and the Role of Interferon Gamma and Interleukin 15 in Its Pathogenesis
Murphy MJ, Gruenstein D, Wang A, Peterson D, Levitt J, King B, Damsky W. Treatment of Persistent Erythema Multiforme With Janus Kinase Inhibition and the Role of Interferon Gamma and Interleukin 15 in Its Pathogenesis. JAMA Dermatology 2021, 157: 1477-1482. PMID: 34757416, PMCID: PMC8581795, DOI: 10.1001/jamadermatol.2021.4084.Peer-Reviewed Original ResearchConceptsPersistent erythema multiformeErythema multiformeJanus kinase (JAK) inhibitionBiopsy specimensInterleukin-15Interferon gammaMajor tertiary referral centreImportant cytokine mediatorMean disease durationMarked clinical improvementTertiary referral centerRetrospective case seriesCase series studySkin biopsy specimensMultiple treatment approachesKinase inhibitionClinical improvementDisease durationReferral centerConsecutive patientsTofacitinib treatmentCase seriesCytokine mediatorsFemale patientsRNA sequencingCytokine RNA In Situ Hybridization Permits Individualized Molecular Phenotyping in Biopsies of Psoriasis and Atopic Dermatitis
Wang A, Fogel AL, Murphy MJ, Panse G, McGeary MK, McNiff JM, Bosenberg M, Vesely MD, Cohen JM, Ko CJ, King BA, Damsky W. Cytokine RNA In Situ Hybridization Permits Individualized Molecular Phenotyping in Biopsies of Psoriasis and Atopic Dermatitis. JID Innovations 2021, 1: 100021. PMID: 34909719, PMCID: PMC8659380, DOI: 10.1016/j.xjidi.2021.100021.Peer-Reviewed Original ResearchAtopic dermatitisAtopic dermatitis casesInflammatory skin diseaseInflammatory skin disorderSubset of casesSitu hybridizationCytokine RNARoutine biopsyCytokine expressionPredominant cytokinePsoriasis casesCytokine targetsTreatment selectionDermatitis casesSkin disordersPsoriasis biomarkersSkin diseasesIndividual cytokinesIndividualized evaluationPsoriasisBiopsyBulk RNA sequencingCytokinesMolecular phenotypingPatients
2020
Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis
Murphy MJ, Cohen JM, Vesely MD, Damsky W. Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis. Journal Of The American Academy Of Dermatology 2020, 86: 1080-1091. PMID: 33307146, DOI: 10.1016/j.jaad.2020.12.010.Peer-Reviewed Original ResearchConceptsParadoxical reactionSystematic reviewNecrosis factor α inhibitorsTumor necrosis factor αSpectrum of manifestationsNecrosis factor αAntibody-based therapiesInterleukin-12/23IL-23IL-12/23Clinical featuresCutaneous reactionsEczematous eruptionInflammatory disordersProinflammatory cytokinesΑ inhibitorsRetrospective analysisIL-4RαFactor αPotential mechanismsDermatologyTherapyInhibitorsAntibodiesReaction patterns